Advanced search
1 file | 1.64 MB Add to list

NGS-analysis to the rescue : dual checkpoint inhibition in metastatic osteosarcoma : a case report and review of the literature

Laure Nuytemans (UGent) , Gwen Sys (UGent) , David Creytens (UGent) and Lore Lapeire (UGent)
Author
Organization
Abstract
Background: The prognosis and treatment of metastatic osteosarcoma have not changed in the last decades and the responses to chemotherapy in this setting are disappointing. In the past years, immunotherapy has found its place in the treatment of different tumor types. Its role in the treatment of sarcomas, and in particular osteosarcoma, is less clear. Next-generation sequencing (NGS) can help identify patients who could benefit from immunotherapy. Methods: Single case study and review of the literature Case summary and intervention: We discuss a case of a 26-year-old man with a metastatic osteosarcoma not responsive to several lines of standard chemotherapy. NGS-analysis of resected tumor tissue revealed amplification of PD-L1 and PD-L2, which is associated in literature with response to anti-PD-1/PD-L1 blockade in other tumor types and in osteosarcoma mouse models. Treatment of our patient with the combination of an anti-PD-1 antibody (Nivolumab) and an anti-CTLA4 antibody (Ipilimumab) showed a stabilization of life-threatening retrocardiac tumoral masses that had previous significantly progressed despite radiotherapy, while one bone lesion in the right os ilium was growing and needed treatment with concomitant radiotherapy. Conclusion: To our knowledge, this is the first case report of a metastasized osteosarcoma patient with no further standard treatment options being treated with dual checkpoint inhibition. A complete stabilization of life-threatening retrocardiac lesions could be achieved and with the addition of radiotherapy to a growing bone lesion, the patient is still doing well. NGS-analysis can help identify druggable targets in patients with rare tumors with limited treatment options.
Keywords
Osteosarcoma, PD-L1 amplification, nivolumab, ipilimumab, immunotherapy, LIGAND 1 EXPRESSION, BLOCKADE, SARCOMA, PD-1

Downloads

  • (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.64 MB

Citation

Please use this url to cite or link to this publication:

MLA
Nuytemans, Laure, et al. “NGS-Analysis to the Rescue : Dual Checkpoint Inhibition in Metastatic Osteosarcoma : A Case Report and Review of the Literature.” ACTA CLINICA BELGICA, 2020.
APA
Nuytemans, L., Sys, G., Creytens, D., & Lapeire, L. (2020). NGS-analysis to the rescue : dual checkpoint inhibition in metastatic osteosarcoma : a case report and review of the literature. ACTA CLINICA BELGICA.
Chicago author-date
Nuytemans, Laure, Gwen Sys, David Creytens, and Lore Lapeire. 2020. “NGS-Analysis to the Rescue : Dual Checkpoint Inhibition in Metastatic Osteosarcoma : A Case Report and Review of the Literature.” ACTA CLINICA BELGICA.
Chicago author-date (all authors)
Nuytemans, Laure, Gwen Sys, David Creytens, and Lore Lapeire. 2020. “NGS-Analysis to the Rescue : Dual Checkpoint Inhibition in Metastatic Osteosarcoma : A Case Report and Review of the Literature.” ACTA CLINICA BELGICA.
Vancouver
1.
Nuytemans L, Sys G, Creytens D, Lapeire L. NGS-analysis to the rescue : dual checkpoint inhibition in metastatic osteosarcoma : a case report and review of the literature. ACTA CLINICA BELGICA. 2020;
IEEE
[1]
L. Nuytemans, G. Sys, D. Creytens, and L. Lapeire, “NGS-analysis to the rescue : dual checkpoint inhibition in metastatic osteosarcoma : a case report and review of the literature,” ACTA CLINICA BELGICA, 2020.
@article{8633780,
  abstract     = {Background: The prognosis and treatment of metastatic osteosarcoma have not changed in the last decades and the responses to chemotherapy in this setting are disappointing. In the past years, immunotherapy has found its place in the treatment of different tumor types. Its role in the treatment of sarcomas, and in particular osteosarcoma, is less clear. Next-generation sequencing (NGS) can help identify patients who could benefit from immunotherapy.
Methods: Single case study and review of the literature 
Case summary and intervention: We discuss a case of a 26-year-old man with a metastatic osteosarcoma not responsive to several lines of standard chemotherapy. NGS-analysis of resected tumor tissue revealed amplification of PD-L1 and PD-L2, which is associated in literature with response to anti-PD-1/PD-L1 blockade in other tumor types and in osteosarcoma mouse models. Treatment of our patient with the combination of an anti-PD-1 antibody (Nivolumab) and an anti-CTLA4 antibody (Ipilimumab) showed a stabilization of life-threatening retrocardiac tumoral masses that had previous significantly progressed despite radiotherapy, while one bone lesion in the right os ilium was growing and needed treatment with concomitant radiotherapy.
Conclusion: To our knowledge, this is the first case report of a metastasized osteosarcoma patient with no further standard treatment options being treated with dual checkpoint inhibition. A complete stabilization of life-threatening retrocardiac lesions could be achieved and with the addition of radiotherapy to a growing bone lesion, the patient is still doing well. NGS-analysis can help identify druggable targets in patients with rare tumors with limited treatment options.},
  author       = {Nuytemans, Laure and Sys, Gwen and Creytens, David and Lapeire, Lore},
  issn         = {1784-3286},
  journal      = {ACTA CLINICA BELGICA},
  keywords     = {Osteosarcoma,PD-L1 amplification,nivolumab,ipilimumab,immunotherapy,LIGAND 1 EXPRESSION,BLOCKADE,SARCOMA,PD-1},
  language     = {eng},
  pages        = {7},
  title        = {NGS-analysis to the rescue : dual checkpoint inhibition in metastatic osteosarcoma : a case report and review of the literature},
  url          = {http://dx.doi.org/10.1080/17843286.2019.1683129},
  year         = {2020},
}

Altmetric
View in Altmetric
Web of Science
Times cited: